The Psychedelic Therapeutics and Drug Development Conference is an annual event that brings together leading researchers, and leaders from academia, industry, non-profits, and government. The conference focuses on the challenges and opportunities in the research and development of psychedelics for various health conditions with considerable unmet need. It highlights progress towards regulatory approval and the potential of psychedelics to treat conditions like inflammatory/autoimmune disorders, brain injury, pain, PTSD, anxiety, ADHD, headaches, depression, and opioid use disorder.
The conference is designed for a broad audience of professionals involved in the psychedelics space. This includes C-level executives, vice presidents, and professionals in business development, regulatory affairs, R&D, and clinical development. Scientists, chemists, pharmacists, investigators, and project managers will also find the content valuable, as will investors, analysts, attorneys, and healthcare practitioners.
Attendees can expect to hear about the latest studies, clinical trials, and advancements directly from the researchers involved. The conference features presentations and panel discussions on topics such as clinical trial design, intellectual property, regulatory guidance, drug delivery, commercialization, and legal issues. It also provides networking opportunities to connect with leading scientists, clinicians, and industry professionals.
This is the 6th annual event, which indicates it has been running for several years. Details about this event's history are not yet widely available.